In-Depth Study on Acute Coronary Syndrome - Pipeline Review, H2 2016

Acute Coronary Syndrome - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Acute Coronary Syndrome (Cardiovascular) pipeline landscape.

Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high blood pressure, high blood cholesterol, cigarette smoking and Type 2 diabetes. Treatment includes beta blockers, calcium channel blockers, cholesterol-lowering drugs and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBS).

Complete report available @ Acute Coronary Syndrome - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Coronary Syndrome (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 3, 9 and 1 respectively.Acute Coronary Syndrome.

Acute Coronary Syndrome (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Coronary Syndrome (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Coronary Syndrome (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Coronary Syndrome (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Coronary Syndrome (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

advanceCor GmbH Arena Pharmaceuticals, Inc. Ascendia Pharmaceuticals LLC Athera Biotechnologies AB Bayer AG Cardiome Pharma Corp. Cerenis Therapeutics Holding SA CSL Limited Esperion Therapeutics, Inc. HitGen LTD Japan Tobacco Inc. Lee's Pharmaceutical Holdings Limited LipimetiX Development Inc MedImmune LLC Pfizer Inc. The Medicines Company Verseon Corporation

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###